Randomised phase 3 trial of radiation plus androgen deprivation therapy with or without enzalutamide for high risk, clinically localised, prostate cancer
Primary Sponsor
ANZUP
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG), NHMRC Clinical Trials Centre
Accrual Target
800
Final Accrual
802
Closing Date of Accrual
30 June 2018
Trial Contact
enzarad.study@sydney.edu.au
Related Post
24 June, 2025
TROG 2024 Annual Research Report highlights a year of achievements
LATEST NEWS: 24 JUNE 2025 The latest annual report
11 June, 2025
Trial Could Prove a Game-Changer for Treating High-Risk Skin Cancer
LATEST NEWS: 11 JUNE 2025 New findings from a
